Drug Profile
Surotomycin - Merck & Co
Alternative Names: CB-183,315; CB-315; CDAD therapy - Merck; MK-4261Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Cubist Pharmaceuticals
- Developer Merck & Co
- Class Antibacterials; Lactones; Lipopeptides; Peptides
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 26 Feb 2016 Discontinued - Phase-III for Clostridium difficile infections in USA, Canada, South Korea, Australia, United Kingdom, Sweden, Spain, Poland, Poland, Italy, Israel, Hungary, Germany, France, Czech Republic, Belgium, Austria and New Zealand (PO), because of unfavourable efficacy data and commercial opportunity (Merck & Co. 10-K, February 2016)
- 04 May 2015 Phase-III clinical trials in Clostridium difficile infections in Australia, South Korea and New Zealand (PO)
- 01 May 2015 Cubist Pharmaceuticals completes a phase III trial in Clostridium difficile infections in USA, Canada, Israel and European Union (NCT01597505)